bluebird bio Announces Participation in Upcoming Investor Conferences Read more about bluebird bio Announces Participation in Upcoming Investor Conferences
bluebird bio to Present at the Leerink Global Healthcare Conference Read more about bluebird bio to Present at the Leerink Global Healthcare Conference
FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major Read more about FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major
bluebird bio Announces Transition of Chief Scientific Officer Read more about bluebird bio Announces Transition of Chief Scientific Officer
bluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference Read more about bluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference
bluebird bio Announces Pricing of Public Offering of Common Stock Read more about bluebird bio Announces Pricing of Public Offering of Common Stock
bluebird bio Announces Proposed Public Offering of Common Stock Read more about bluebird bio Announces Proposed Public Offering of Common Stock
bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free Read more about bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free
bluebird bio Reports Fiscal Third Quarter 2014 Financial Results Read more about bluebird bio Reports Fiscal Third Quarter 2014 Financial Results
James M. DeTore joins bluebird bio as Chief Financial Officer Read more about James M. DeTore joins bluebird bio as Chief Financial Officer